Other Search Results
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy SJ Lunt 1,5,7 , C Cawthorne 2,3,7 , M Ali 1 , BA Telfer 1 , M Babur...

Typical Treatment of Acute Myeloid Leukemia (Except APL) | American Cancer Society

The acute promyelocytic leukemia (APL) subtype of AML is treated differently. ; Treatment for AML often needs to start as quickly as possible after it is diagnosed because it can progress very quickly. Sometimes another type of treatment needs to be started even before the chemo has had a chance to work. ; Some people with AML have very high numbers of leukemia cells in their blood when they are first diagnosed, which can cause problems with normal blood circulation. This is called leukostasis, and it needs to be treated right away.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease

Metastases cause most cancer-related deaths. We investigated the use of hypoxia-selective cytotoxins as adjuvants to radiotherapy in the control of metastatic tumour growth. The NLCQ-1...

Cancers | Free Full-Text | Treatment Options for Paediatric Anaplastic Large Cel

IDM-HiDAC = intermediate dose MTX-high-dose cytarabine, Chemo. = multi-agent chemotherapy. Given that ALCL was not recognised as a distinct form of NHL until 1989, most patients prior to...

Transforming Lives Glycobiology-based Therapeutics

Transforming Lives Glycobiology-based Therapeutics June 2024 | NASDAQ: GLYC 2 • To the extent that statements contained in this presentation are not descriptions of historical facts, they...

Biomedicines | Free Full-Text | Transplant Eligible and Ineligible Elderly Patie

Abstract The management of elderly patients diagnosed with acute myelogenous leukemia (AML) is complicated by high relapse risk and comorbidities that often preclude access to allogeneic...

JCM | Free Full-Text | Current Approaches in the Treatment of Relapsed and Refra

AML presenting as clinical relapse may be from three underlying sources: (1) chemo-sensitive... doses (HIDAC), and in combination with other therapeutic agents [12,13]. In general, patients...

Cancers | Free Full-Text | A Phase 1B Clinical Study of Combretastatin A1 Diphos

Abstract Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in murine xenograft...

Superior outcome of patients with favorable-risk acute myeloid leukemia using co - 전자자원 상세

Share export Citation Print My folder Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation. Authors Beyar...

Devendra Hiwase - Research profile

About 144 Publications 7,111 Reads 1,608 Citations Citations since 2017 66 Research Items 1017 Citations Learn about citations on ResearchGate Introduction Skills and Expertise Cell Death...

Copyright © www.babybloodtype.com. All rights reserved.
policy sang_list